Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 7 (2010), Issue 12 (December)

  1. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    JAMA, 304(21): 2373-80. [Abstract] [Full-text]
  2. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    JAMA, 304(21): 2373-80. [Abstract] [Full-text]
  3. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
    J Natl Cancer Inst, 102(23): 1760-70. [Abstract] [Full-text]
  4. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.
    J Natl Cancer Inst, 102(23): 1780-93. [Abstract] [Full-text]
  5. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
    Am J Clin Oncol, 33(6): 619-23. [Abstract] [Full-text]
  6. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
    Am J Clin Oncol, 33(6): 609-13. [Abstract] [Full-text]
  7. Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells.
    Nat Cell Biol, 12(12): 1194-204. [Abstract] [Full-text]
  8. Metabolic alterations and targeted therapies in prostate cancer.
    J Pathol, 223(2): 283-94. [Abstract] [Full-text]
  9. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer.
    J Pathol, 223(1): 81-7. [Abstract] [Full-text]
  10. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy.
    Urology, 76(6): 1434-9. [Abstract] [Full-text]
  11. Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
    Urology, 76(6): 1519.e8-13. [Abstract] [Full-text]
  12. Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer.
    Urology, 76(6): 1409-13. [Abstract] [Full-text]
  13. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies.
    Urology, 76(6): 1506-11. [Abstract] [Full-text]
  14. Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence.
    Urology, 76(6): 1451-5. [Abstract] [Full-text]
  15. Radical cystectomy in patients previously treated for localized prostate cancer.
    Urology, 76(6): 1430-3. [Abstract] [Full-text]
  16. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells.
    Gene, 471(1): 1-12. [Abstract] [Full-text]
  17. cAMP and fibroblast growth factor 2 regulate bone sialoprotein gene expression in human prostate cancer cells.
    Gene, 471(1): 1-12. [Abstract] [Full-text]
  18. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients.
    Am J Hum Genet, 87(6): 802-12. [Abstract] [Full-text]
  19. Endoglin suppresses human prostate cancer metastasis.
    Clin Exp Metastasis, 28(1): 39-53. [Abstract] [Full-text]
  20. Endoglin suppresses human prostate cancer metastasis.
    Clin Exp Metastasis, 28(1): 39-53. [Abstract] [Full-text]
  21. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
  22. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
  23. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
  24. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
  25. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
  26. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
  27. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
  28. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
  29. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
  30. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
  31. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
  32. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
  33. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
  34. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
  35. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
  36. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
  37. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
  38. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
  39. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
  40. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
  41. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat.
    Int J Radiat Oncol Biol Phys, 79(1): 239-46. [Abstract] [Full-text]
  42. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
  43. Electromagnetic-guided dynamic multileaf collimator tracking enables motion management for intensity-modulated arc therapy.
    Int J Radiat Oncol Biol Phys, 79(1): 312-20. [Abstract] [Full-text]
  44. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
    Int J Radiat Oncol Biol Phys, 79(1): 195-201. [Abstract] [Full-text]
  45. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Int J Radiat Oncol Biol Phys, 79(1): 179-87. [Abstract] [Full-text]
  46. Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.
    J Urol, 185(1): 305-14. [Abstract] [Full-text]
  47. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    J Urol, 185(1): 17-23. [Abstract] [Full-text]
  48. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    J Urol, 185(1): 126-31. [Abstract] [Full-text]
  49. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
    J Urol, 185(1): 121-5. [Abstract] [Full-text]
  50. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.
    J Urol, 185(1): 132-7. [Abstract] [Full-text]
  51. Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.
    J Urol, 185(1): 111-5. [Abstract] [Full-text]
  52. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
    J Urol, 185(1): 116-20. [Abstract] [Full-text]
  53. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.
    J Urol, 185(1): 104-10. [Abstract] [Full-text]
  54. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Hum Pathol, 42(1): 11-7. [Abstract] [Full-text]
  55. Interobserver and intraobserver reproducibility in digital and routine microscopic assessment of prostate needle biopsies.
    Hum Pathol, 42(1): 68-74. [Abstract] [Full-text]
  56. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat.
    Int J Radiat Oncol Biol Phys, 79(1): 239-46. [Abstract] [Full-text]
  57. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
  58. Electromagnetic-guided dynamic multileaf collimator tracking enables motion management for intensity-modulated arc therapy.
    Int J Radiat Oncol Biol Phys, 79(1): 312-20. [Abstract] [Full-text]
  59. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
    Int J Radiat Oncol Biol Phys, 79(1): 195-201. [Abstract] [Full-text]
  60. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Int J Radiat Oncol Biol Phys, 79(1): 179-87. [Abstract] [Full-text]
  61. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions.
    Biochem Pharmacol, 81(2): 203-10. [Abstract] [Full-text]
  62. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
    Cancer Genet Cytogenet, 203(2): 230-7. [Abstract] [Full-text]
  63. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.
    Cancer Res, 70(24): 10182-91. [Abstract] [Full-text]
  64. Reduction in physician reimbursement and use of hormone therapy in prostate cancer.
    J Natl Cancer Inst, 102(24): 1826-34. [Abstract] [Full-text]
  65. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Cancer Sci, 102(1): 51-6. [Abstract] [Full-text]
  66. XMRV: a new virus in prostate cancer?
    Cancer Res, 70(24): 10028-33. [Abstract] [Full-text]
  67. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility.
    Cancer Sci, 102(1): 245-52. [Abstract] [Full-text]
  68. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Cancer Sci, 102(1): 51-6. [Abstract] [Full-text]
  69. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility.
    Cancer Sci, 102(1): 245-52. [Abstract] [Full-text]
  70. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
  71. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
  72. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
  73. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
  74. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
    Exp Cell Res, 317(3): 262-75. [Abstract] [Full-text]
  75. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
    Tumour Biol, 32(1): 203-13. [Abstract] [Full-text]
  76. Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer.
    J Med Internet Res, 12(4): e67. [Abstract] [Full-text]
  77. Thrombin expression in prostate: a novel finding.
    Cancer Invest, 29(1): 62-7. [Abstract] [Full-text]
  78. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.
    Med Care, 49(1): 59-66. [Abstract] [Full-text]
  79. Thrombin expression in prostate: a novel finding.
    Cancer Invest, 29(1): 62-7. [Abstract] [Full-text]
  80. The prevalence, correlates, and impact of logically inconsistent preferences in utility assessments for joint health states in prostate cancer.
    Med Care, 49(1): 59-66. [Abstract] [Full-text]
  81. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
    Br J Radiol, 84(997): 31-7. [Abstract] [Full-text]
  82. Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy.
    Acta Oncol, 50(1): 25-34. [Abstract] [Full-text]
  83. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
    Acta Oncol, 50(1): 127-33. [Abstract] [Full-text]
  84. Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map.
    AJR Am J Roentgenol, 196(1): 123-9. [Abstract] [Full-text]
  85. Initial treatment costs of organ-confined prostate cancer: a general perspective.
    BJU Int, 107(1): 1-3. [Abstract] [Full-text]
  86. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    BJU Int, 107(1): 28-39. [Abstract] [Full-text]
  87. Trifecta outcomes after robot-assisted laparoscopic radical prostatectomy.
    BJU Int, 107(1): 100-4. [Abstract] [Full-text]
  88. Documenting the location of prostate biopsies with image fusion.
    BJU Int, 107(1): 53-7. [Abstract] [Full-text]
  89. Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979-2006.
    BJU Int, 107(1): 40-5. [Abstract] [Full-text]
  90. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.
    BJU Int, 107(1): 126-34. [Abstract] [Full-text]
  91. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
    Prostate, 71(2): 168-83. [Abstract] [Full-text]
  92. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
    Prostate, 71(2): 125-33. [Abstract] [Full-text]
  93. Meta-analysis of genome-wide and replication association studies on prostate cancer.
    Prostate, 71(2): 209-24. [Abstract] [Full-text]
  94. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
    Prostate, 71(2): 184-96. [Abstract] [Full-text]
  95. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
    Prostate, 71(2): 157-67. [Abstract] [Full-text]
  96. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
    Prostate, 71(2): 111-24. [Abstract] [Full-text]
  97. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
    Prostate, 71(2): 134-46. [Abstract] [Full-text]
  98. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
  99. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
    Prostate, 71(2): 168-83. [Abstract] [Full-text]
  100. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
    Prostate, 71(2): 125-33. [Abstract] [Full-text]
  101. Meta-analysis of genome-wide and replication association studies on prostate cancer.
    Prostate, 71(2): 209-24. [Abstract] [Full-text]
  102. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
    Prostate, 71(2): 184-96. [Abstract] [Full-text]
  103. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
    Prostate, 71(2): 157-67. [Abstract] [Full-text]
  104. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
    Prostate, 71(2): 111-24. [Abstract] [Full-text]
  105. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
    Prostate, 71(2): 134-46. [Abstract] [Full-text]
  106. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
  107. Prostate cancer risk and exposure to pesticides in British Columbia farmers.
    Prostate, 71(2): 168-83. [Abstract] [Full-text]
  108. Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.
    Prostate, 71(2): 125-33. [Abstract] [Full-text]
  109. Meta-analysis of genome-wide and replication association studies on prostate cancer.
    Prostate, 71(2): 209-24. [Abstract] [Full-text]
  110. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
    Prostate, 71(2): 184-96. [Abstract] [Full-text]
  111. Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.
    Prostate, 71(2): 157-67. [Abstract] [Full-text]
  112. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
    Prostate, 71(2): 111-24. [Abstract] [Full-text]
  113. Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
    Prostate, 71(2): 134-46. [Abstract] [Full-text]
  114. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Int J Cancer, 128(4): 962-73. [Abstract] [Full-text]
  115. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor.
    Cell Signal, 23(3): 507-15. [Abstract] [Full-text]
  116. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro.
    Carcinogenesis, 32(1): 93-101. [Abstract] [Full-text]
  117. DNA damage phenotype and prostate cancer risk.
    Mutat Res, 719(1): 41-6. [Abstract] [Full-text]
  118. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
    J Nucl Med, 52(1): 81-9. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience